# THE LANCET Global Health

## Supplementary appendix

This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors.

Supplement to: Benjamin-Chung J, Crider YS, Mertens A, et al. Household finished flooring and soil-transmitted helminth and *Giardia* infections among children in rural Bangladesh and Kenya: a prospective cohort study. *Lancet Glob Health* 2021; **9**: e301–08.

## Appendix to Household finished flooring and soil-transmitted helminth and Giardia infections among children in rural Bangladesh and Kenya: a prospective cohort study

#### Appendix 1. Outcome measurement

#### Stool collection and storage

Field staff provided primary caregivers of study participants with sterile containers. They returned the following morning to collect stool from the child's most recent defecation event. After stool collection, all study participants received a single dose of albendazole. Stool specimens were transported on ice to the field laboratory in each country, and 1 g of stool was archived in 1 ml of 100% ethanol. Stool as at -20°C until it was moved to a -80°C freezer.

#### Soil-transmitted helminth detection using Kato-Katz

On the day of stool collection, trained technicians performed double-slide Kato- Katz on fresh stool within 30 minutes of preparing each sample. Field staff enumerated *Ascaris lumbricoides*, hookworm, and *Trichuris trichiura* ova. For quality assurance, in Bangladesh 10% of slides were evaluated independently by two technicians, and 5% were evaluated by the same experienced parasitologist who conducted Kato-Katz training. In Kenya, 10% of slides were evaluated by an expert parasitologist.

#### Soil-transmitted helminth detection using Multi-parallel qPCR

Preserved stool samples from Bangladesh were shipped to Smith College in Northampton, MA, United States approximately 1–2 years after stool collection for qPCR analyses. Before shipment lab technicians evaporated from ethanol all samples in order to comply with shipping regulations. Samples were shipped on dry ice. Upon arrival at Smith College, samples were stored at -20°C until analysis. Preserved stool samples from Kenya were transported to the Eastern and Southern Africa Centre of International Parasite Control laboratory at the Kenya Medical Research Institute in Nairobi, Kenya, for analysis.

Lab technicians extracted DNA using the FastDNA Spin Kit for Soil (MP Biomedicals, Solon, OH) using a previously published modified version of the manufacturer's methodology.<sup>1</sup> Lab technicians used an internal amplification control (IAC) plasmid during the DNA extraction to ensure successful isolation and adequate DNA recovery. The mean and standard deviation of the mean quantitation cycle (Cq) value for IAC results was calculated from all samples. Lab technicians performed experimental qPCR reactions using multi-parallel assays that target non-coding repetitive sequences to detect A. lumbricoides<sup>2</sup>, T. trichiura, Necator americanus, Ancylostoma duodenale<sup>3</sup> and Ancylostoma ceylanicum<sup>4</sup> (Bangladesh only). Lab technicians tested all samples in replicate reactions. We classified samples as positive if amplification occurred in both reactions with a Cq value of <40 and samples which produced Cq values  $\geq 40$  in both replicate reactions or failed to amplify in both replicate reactions as negative. A random subsample of stool samples from Kenya were shipped to Smith College for quality assurance.

#### G. duodenalis detection using qPCR (Bangladesh)

Lab technicians extracted DNA from 200 mg of stool using the QIAamp Fast DNA Stool Mini Kit (QIAGEN, Hilden, Germany). They eluted the DNA in 200  $\mu$ l of ATE buffer (supplied with the QIAGEN kit). The protozoa were measured by multiplex real-time PCR using a previously published protocol.<sup>5</sup> Primers

<sup>&</sup>lt;sup>1</sup>Mejia R, Vicuna Y, Broncano N, Sandoval C, Vaca M, Chico M, et al. A Novel, Multi-Parallel, Real-Time Polymerase Chain Reaction Approach for Eight Gastrointestinal Parasites Provides Improved Diagnostic Capabilities to Resource-Limited At-Risk Populations. Am J Trop Med Hyg. 2013; 88: 1041–1047. https://doi.org/10.4269/ajtmh.12-0726 PMID: 23509117

<sup>&</sup>lt;sup>2</sup>Pilotte N, Maasch JRMA, Easton AV, Dahlstrom E, Nutman TB, Williams SA. Targeting a highly repeated germline DNA sequence for improved real-time PCR-based detection of Ascaris infection in human stool. *PLoS Negl Trop Dis. 2019*; 13: e0007593. https://doi.org/10.1371/journal.pntd.0007593 PMID: 31329586

<sup>&</sup>lt;sup>3</sup>Pilotte N, Papaiakovou M, Grant JR, Bierwert LA, Llewellyn S, McCarthy JS, et al. Improved PCR- Based Detection of Soil Transmitted Helminth Infections Using a Next-Generation Sequencing Approach to Assay Design. *PLoS Negl Trop Dis.* 2016; 10: e0004578. https://doi.org/10.1371/journal. pntd.0004578 PMID: 27027771

<sup>&</sup>lt;sup>4</sup>Papaiakovou M, Pilotte N, Grant JR, Traub RJ, Llewellyn S, McCarthy JS, et al. A novel, species-spe- cific, real-time PCR assay for the detection of the emerging zoonotic parasite Ancylostoma ceylanicum in human stool. *PLoS Negl Trop Dis.* 2017; 11: e0005734. https://doi.org/10.1371/journal.pntd.0005734 PMID: 28692668

<sup>&</sup>lt;sup>5</sup>Haque R, Roy S, Siddique A, et al. Multiplex real-time PCR assay for detection of Entamoeba histolytica, Giardia intestinalis, and Cryptosporidium spp. Am J Trop Med Hyg, 2007; 76(4): 713-717.

and probes were purchased from Integrated DNA Technologies (Singapore). Amplification reactions were performed in a volume of 25 µL with 12.5 µL of QIAGEN Multiplex PCR Master Mix (QIAGEN, Hilden, Germany). Each reaction contained an additional 0.4 µM of each Gd-80F, Gd-127R primers and 0.04 µM of Gd-FT probes and 3 µl of the DNA sample. Samples were initial denatured for 15 minutes at 95°C, denatured at 95°C for 20 seconds for 40 cycles, and annealed at 60°C for 1 minute with fluorescence data collection. Lab technicians performed amplification and analysis on the CFX96 Real-Time System (BioRad, Hercules, CA). Each run included three positive controls and one negative control. We classified a sample as positive if its Ct was <40.

#### G. duodenalis detection using ELISA (Kenya)

Lab technicians at Kenya Medical Research Institute in Nairobi, Kenya, analyzed stool by monoclonal enzyme-linked immunosorbent assay (ELISA) (Giardia II, Alere International, Galway, Ireland) to detect G. duodenalis cysts. Samples were measured in duplicate; discrepant samples were rerun.

#### Appendix Figure 1. Enrollment flow chart



Appendix Figure 2. Eggs per gram among individuals with STH infections detected by Kato-Katz at two-year follow-up by household flooring status at enrollment



Appendix Figure 3. Adjusted prevalence ratios for household flooring status at enrollment and soil-transmitted helminth and Giardia prevalence at two-year follow-up stratified by potential effect modifiers



#### A) Bangladesh

Finished floors includes wood, cement, or tile household floors; unfinished floors were made of soil or earth. In the plots error bars indicate 95% confidence intervals. Prevalence ratios (PRs) compared the prevalence of infection at two-year follow-up in children with improved household flooring at enrolment to those with unimproved household flooring at enrolment. Adjusted PRs control for potential confounders associated with the outcome (see list in the Methods section). Confidence intervals were adjusted for clustering at the village level. Results are not shown for A. *lumbricoides* in Panel A) for deworming because of sparse data. All interaction p-values were  $\geq 0.05$  except for the p-value for G. duodenalis in Bangladesh for child age.





The predicted probability of having a finished floor adjusting for covariates defined above was estimated using an ensemble machine learning algorithm and the following covariates if they were associated with the outcome using a likelihood ratio test (p-value <0.2): month, child age, child sex, birth order (Bangladesh only), mother's age, mother's education, mother's height, number of household members  $\leq 18$  years, total number of individuals in the compound, food insecurity, household assets, and intervention arm.



Appendix Figure 5. Sensitivity analysis accounting for changes in household flooring status during the follow-up period

Finished floors includes wood, cement, or tile household floors; unfinished floors were made of soil or earth. In the plots error bars indicate 95% confidence intervals. Prevalence ratios (PRs) compared the prevalence of infection at two-year follow-up in children with improved household flooring at enrolment to those with unimproved household flooring at enrolment. Adjusted PRs control for potential confounders associated with the outcome (see list in the Methods section). Confidence intervals were adjusted for clustering at the village level. Results are not shown for T. trichiura in Kenya for Sensitivity Analysis 1 because of sparse data.

Primary analysis: Uses household flooring status at enrollment regardless of changes at two-year follow-up.

Sensitivity analysis 1: Excludes households that changed flooring status between enrollment and two-year follow-up.

Sensitivity analysis 2: Includes households that improved their household flooring status between enrollment and follow-up in the exposure group.

Appendix Table 1. Soil-transmitted helminth and *Giardia duodenalis* prevalence and median Cq value detected by qPCR at two-year follow-up by household flooring status at enrollment

		Finished	l floo	rs	Unfinished floors			
	N	Prevalence (95% CI)	Ν	Median Cq value in positive samples (range)	N	Prevalence (95%CI)	N	Median Cq value in positive samples (range)
Bangladesh								
A. lumbricoides	255	$2.0\ (0.4,\ 3.7)$	5	24.8 (22.3, 31.2)	2,544	$13.8\ (12.0,\ 15.5)$	350	23.3 (16.4, 36.1)
A. ceylanicum	255	4.3(1.6, 7.4)	11	$24.1 \ (16.5, \ 37.8)$	2,544	3.7(2.9, 4.6)	95	23.5(14.4, 37.1)
N. americanus	255	5.1 (2.5, 8.2)	13	20.2 (13.9, 27.2)	2,544	19.7 (17.7, 21.9)	502	20.8(14.0, 35.5)
T. trichiura	255	5.5(2.9, 8.6)	14	27.7 (25.2, 36.8)	2,544	12.9(11.0, 14.9)	329	27.7(21.4, 40.0)
Any STH	255	14.5 (9.8, 19.7)	_	_	2,544	36.7 (34.1, 39.4)	_	_
$G. \ du odenalis$	661	19.4 (16.1, 22.8)	_	_	6,233	33.2 (31.7, 34.6)	_	_
Kenya								
A. lumbricoides	174	11.5(7.0, 17.5)	20	26.2(18.5, 33.7)	2,924	23.7 (21.3, 25.9)	692	24.8 (16.0, 39.6)
N. americanus	174	3.4(1.1, 6.5)	6	28.8(18.7, 34.8)	2,923	7.2(5.7, 8.8)	209	24.5(11.1, 39.2)
T. trichiura	174	$1.1 \ (0.0, \ 3.1)$	2	30.0(27.3, 32.7)	2,922	$1.2 \ (0.6, \ 2.0)$	35	28.5(23.1, 34.6)
Any STH	173	14.5 (9.3, 20.4)	_	_	2,920	29.2 (26.6, 31.8)	_	_
G. duodenalis	456	$31.4\ (27.0,\ 35.9)$	-	_	$^{8,436}$	$39.1 \ (37.8, \ 40.4)$	—	_

This table excludes observations with propensity scores in the highest and lowest 1% of the observed distribution of propensity scores in each country. Propensity scores estimated the probability a child lived in a household with a finished floor conditioning on the following covariates if they were associated with the outcome using a likelihood ratio test (p-value <0.2): month, child age, child sex, birth order (Bangladesh only), mother's age, mother's education, mother's height, number of household members  $\leq 18$  years, total number of individuals in the compound, food insecurity, household assets, and intervention arm. In Kenya, *G. duodenalis* was measured by ELISA, not qPCR. Quantitative estimates of infection intensity were not available for this measure using ELISA.

Appendix Table 2: Soil-transmitted helminth prevalence and infection intensity detected by Kato-Katz at two-year follow-up by household flooring status at enrollment

		Finish	ned floo	ors		Unfinis	hed floo	rs
	N	Prevalence (95% CI)	Ν	Geometric Mean EPG in positive samples (95% CI)	N	Prevalence (95% CI)	Ν	Geometric Mean EPG in positive samples (95% CI)
Bangladesh								
Hookworm	691	2.2(1.2, 3.3)	691	$0.12 \ (0.06, \ 0.18)$	6,496	8.3(7.4, 9.1)	6,496	0.49 (0.43, 0.56)
T. trichiura	691	2.3(1.3, 3.6)	691	0.10(0.05, 0.16)	6,496	7.5(6.6, 8.4)	6,496	$0.43 \ (0.36, \ 0.51)$
Kenya								
A. lumbricoides	471	11.7 (8.5, 14.9)	471	$1.62 \ (0.85, \ 2.70)$	8,568	20.4 (19.1, 21.7)	8,568	4.77(3.67, 6.12)
Any STH	471	$12.1 \ (8.9, \ 15.3)$	_	_	8,568	22.3 (20.9, 23.6)	_	_

In Bangladesh, results for A. lumbricoides are not shown due to concerns about potential misclassification. In Kenya, overall prevalence of any STH in each country including hookworm and T. trichiura.

	Ν	Unadjusted PR (95% CI)	Adjusted PR (95% CI)
Bangladesh			
Hookworm	7,187	$0.26 \ (0.16, \ 0.43)$	$0.65\ (0.39,\ 1.08)$
$T.\ trichiura$	$7,\!187$	$0.31 \ (0.19, \ 0.51)$	$0.57 \ (0.33, \ 0.96)$
Kenya			
A. lumbricoides	9,039	0.57 (0.43, 0.76)	$0.69 \ (0.51, \ 0.93)$
Any STH	9,039	$0.54\ (0.42,\ 0.71)$	$0.66 \ (0.50, \ 0.88)$

Appendix Table 3: Unadjusted and adjusted prevalence ratios for soil-transmitted helminth infection detected by Kato-Katz

Prevalence ratios (PRs) compared the prevalence of infection at two-year follow-up in children with improved household flooring at enrolment. Adjusted PRs control for potential confounders associated with the outcome (see list in the Methods section). Confidence intervals were adjusted for clustering at the village level. In Bangladesh, results for A. *lumbricoides* are not shown due to concerns about potential misclassification.

Appendix	Table	4:	Unadjusted	and	adjusted	soil-transmitted	$\mathbf{helminth}$	fecal	$\mathbf{egg}$	$\operatorname{count}$	differences
detected b	y Kato	-Ka	tz among inf	ected	l individua	als at two-year fol	low-up by i	housel	hold	flooring	g status at
enrollment	t										

	Ν	Unadjusted FECD (95% CI)	Adjusted FECD (95% CI)
Bangladesh			
Hookworm	554	0.37 (-0.63, 1.38)	0.49(-2.40, 3.38)
T. trichiura	502	-0.60 (-0.93, -0.28)	-0.45 (-0.59, -0.32)
Kenya			
A. lumbricoides	$1,\!802$	-0.05 (-0.39, 0.29)	$0.06 \ (-0.05, \ 0.17)$

Fecal egg count differences (FECDs) are defined as the ratio of mean eggs per gram among positive samples detected by Kato-Katz minus one. Adjusted estimates control for potential confounders associated with the outcome (see list in the Methods section). Confidence intervals were adjusted for clustering at the village level. In Bangladesh, results for A. *lumbricoides* are not shown due to concerns about potential misclassification.

	Ν	Unadjusted PR (95% CI)	Adjusted PR (95% CI)
Bangladesh			
A. lumbricoides	2,796	$0.14 \ (0.07, \ 0.28)$	$0.17 \ (0.10, \ 0.30)$
A. ceylanicum	2,796	$1.17 \ (0.53, \ 2.58)$	1.97 (0.85, 4.57)
N. americanus	2,785	0.26(0.16, 0.43)	$0.53 \ (0.40, \ 0.71)$
T. trichiura	2,796	$0.45\ (0.28,\ 0.71)$	$1.11 \ (0.87, \ 1.43)$
Any STH	2,796	$0.40 \ (0.29, \ 0.55)$	$0.71 \ (0.58, \ 0.86)$
$G. \ du odenalis$	$6,\!874$	$0.58\ (0.47,\ 0.71)$	$0.82 \ (0.70, \ 0.95)$
Kenya			
A. lumbricoides	3,059	$0.51 \ (0.27, \ 0.97)$	$0.55\ (0.30,\ 1.03)$
N. americanus	2,961	$0.53 \ (0.18, \ 1.55)$	$0.51 \ (0.15, \ 1.75)$
T. trichiura	2,983	$0.57 \ (0.03, \ 11.61)$	$0.55\ (0.03,\ 10.28)$
Any STH	2,836	0.47 (0.26, 0.84)	$0.52 \ (0.31, \ 0.89)$
$G. \ du odenalis$	$8,\!457$	$0.77 \ (0.65, \ 0.92)$	$0.80 \ (0.66, \ 0.96)$

Appendix Table 5: Unadjusted and adjusted prevalence ratios for infection detected by qPCR or ELISA estimated using targeted maximum likelihood estimation

Prevalence ratios (PRs) compared the prevalence of infection at two-year follow-up in children with improved household flooring at enrolment. Adjusted PRs control for potential confounders associated with the outcome (see list in the Methods section). Confidence intervals were adjusted for clustering at the village level.

Ν	Unadj. Cq Relative Difference (95% CI)	Adj. Cq Relative Difference (95% CI)
355	0.07 (-0.05, 0.18)	$0.10 \ (0.06, \ 0.14)$
106	-0.00(-0.19, 0.18)	0.06 (-0.12, 0.24)
515	-0.04 ( $-0.12$ , $0.04$ )	-0.04 ( $-0.11$ , $0.04$ )
341	0.00(-0.12, 0.12)	0.01 (-0.09, 0.10)
$2,\!195$	$0.01 \ (-0.02, \ 0.04)$	-0.00 ( $-0.03$ , $0.02$ )
712	-0.01 ( $-0.13$ , $0.10$ )	-0.01 ( $-0.11$ , $0.10$ )
206	0.11 (-0.20, 0.41)	0.16 (-0.09, 0.41)
34	$0.01 \ (-0.15, \ 0.18)$	$0.04 \ (-0.09, \ 0.17)$
	N 355 106 515 341 2,195 712 206 34	$\begin{array}{c c} {\rm N} & {\rm Unadj. \ Cq \ Relative} \\ {\rm Difference} \ (95\% \ {\rm CI}) \\ \hline \\ 355 & 0.07 \ (-0.05, \ 0.18) \\ 106 & -0.00 \ (-0.19, \ 0.18) \\ 515 & -0.04 \ (-0.12, \ 0.04) \\ 341 & 0.00 \ (-0.12, \ 0.12) \\ 2,195 & 0.01 \ (-0.02, \ 0.04) \\ \hline \\ 712 & -0.01 \ (-0.13, \ 0.10) \\ 206 & 0.11 \ (-0.20, \ 0.41) \\ 34 & 0.01 \ (-0.15, \ 0.18) \\ \end{array}$

Appendix Table 6: Unadjusted and adjusted Cq relative difference among infected individuals at two-year follow-up by household flooring status at enrollment estimated using TMLE

Cq ratios compared the arithmetic mean Cq value at two-year follow-up in children with improved household flooring at enrolment to those with unimproved household flooring at enrolment. Adjusted Cq ratios control for potential confounders associated with the outcome (see list in the Methods section). Confidence intervals were adjusted for clustering at the village level

		Bang		Kenya				
	Fini	shed floors	Unfin	ished floors	Fini	shed floors	Unfin	ished floors
	Ν	Mean / %	Ν	Mean / %	Ν	Mean / %	Ν	Mean / %
Maternal characteristics								
Mother's age, years	668	24.2	2122	23.7	464	28.6	8070	27.0
Mother's height, cm	666	151.9	2125	151.5	432	161.8	7779	160.3
At least some primary	670	13.3	2146	15.7	468	51.3	8138	77.7
education								
At least some secondary	670	82.8	2146	80.2	468	48.7	8138	22.3
education								
<b>Compound characteristics</b>								
# individuals living in	670	1.7	2146	1.7	468	3.5	8136	3.1
$compound \leq =18 \text{ yrs}$								
Total individuals living in	670	9.9	2146	10.7	468	7.4	8138	8.0
compound								
Household characteristics								
Food secure	670	91.5	2146	89.2	468	96.4	8138	91.3
Has electricity	670	89.4	2146	83.7	468	28.8	8138	6.7
Has improved wall	670	91.9	2146	66.5	468	70.3	8138	0.8
materials								
Has improved roof material	670	100.0	2146	99.9	468	97.6	8138	66.5
$Owns \ge 1 tv$	670	70.7	2146	56.4	468	41.0	8138	11.2
Owns >=1 bicycle	670	35.4	2146	41.7	468	64.3	8138	54.5
Owns >= 1 motorcycle	670	23.0	2146	11.2	468	24.6	8138	8.6
Owns >=1 mobile phone	670	98.5	2146	95.2	468	94.7	8138	81.2
Child characteristics								
Child age, years	670	4.7	2146	4.7	446	3.7	7846	3.6
Male, %	670	49.3	2146	49.1	468	50.9	8138	47.4

Appendix Table 7. Characteristics at enrollment by household finished flooring status excluding observations with extreme propensity score values

This table excludes observations with propensity scores in the highest and lowest 1% of the observed distribution of propensity scores in each country. Propensity scores estimated the probability a child lived in a household with a finished floor conditioning on the following covariates if they were associated with the outcome using a likelihood ratio test (p-value <0.2): month, child age, child sex, birth order (Bangladesh only), mother's age, mother's education, mother's height, number of household members  $\leq 18$  years, total number of individuals in the compound, food insecurity, household assets, and intervention arm.

Appendix Table 8: Sensitivity analysis excluding observations with extreme predicted probabilities of having finished flooring

		Primary ana	lysis	Sensitivity analysis				
	Ν	Unadjusted PR (95% CI)	Adjusted PR (95% CI)	N	Unadjusted PR (95% CI)	Adjusted PR (95% CI)		
Bangladesh								
A. lumbricoides	2,799	$0.14 \ (0.06, \ 0.34)$	$0.34 \ (0.15, \ 0.80)$	1,960	$0.19\ (0.08,\ 0.46)$	$0.35 \ (0.15, \ 0.83)$		
$A.\ ceylanicum$	2,799	$1.16\ (0.55,\ 2.42)$	1.60(0.72, 3.54)	1,960	$1.26\ (0.58,\ 2.75)$	1.39(0.63, 3.08)		
N. americanus	2,799	$0.26\ (0.14,\ 0.46)$	$0.52 \ (0.29, \ 0.94)$	1,960	$0.31 \ (0.17, \ 0.56)$	$0.55\ (0.30,\ 1.00)$		
T. trichiura	2,799	$0.42 \ (0.25, \ 0.72)$	$0.93 \ (0.55, \ 1.59)$	1,960	$0.52 \ (0.31, \ 0.88)$	$0.93 \ (0.54, \ 1.61)$		
Any STH	2,799	$0.40\ (0.28,\ 0.56)$	$0.73 \ (0.52, \ 1.01)$	1,960	0.48(0.34, 0.68)	$0.78 \ (0.55, \ 1.09)$		
$G. \ du odenalis$	$6,\!894$	$0.58\ (0.49,\ 0.70)$	$0.78 \ (0.64, \ 0.95)$	4,811	$0.65\ (0.54,\ 0.78)$	$0.80 \ (0.66, \ 0.98)$		
Kenya								
A. lumbricoides	3,098	$0.49 \ (0.31, \ 0.76)$	$0.61 \ (0.39, \ 0.97)$	2,936	$0.50 \ (0.31, \ 0.78)$	$0.61 \ (0.38, \ 0.97)$		
N. americanus	3,097	0.48(0.21, 1.08)	0.69(0.31, 1.55)	2,935	0.48(0.21, 1.08)	0.70(0.32, 1.56)		
T. trichiura	3,096	0.96(0.24, 3.88)	0.38(0.06, 2.54)	2,934	$0.91 \ (0.22, \ 3.66)$	0.47 (0.07, 3.22)		
Any STH	3,093	0.49(0.34, 0.73)	$0.57 \ (0.37, \ 0.88)$	2,931	$0.50 \ (0.34, \ 0.74)$	$0.58 \ (0.39, \ 0.87)$		
$G. \ du odenalis$	8,892	$0.80\ (0.70,\ 0.92)$	$0.82 \ (0.70, \ 0.97)$	$8,\!433$	$0.81 \ (0.71, \ 0.94)$	$0.84\ (0.73,\ 0.97)$		

Prevalence ratios (PRs) compared the prevalence of infection at two-year follow-up in children with improved household flooring at enrolment. Adjusted PRs control for potential confounders associated with the outcome (see list in the Methods section). Confidence intervals were adjusted for clustering at the village level. Analyses excluded observations with propensity scores in the highest and lowest 1% of the observed distribution of propensity scores in each country. Propensity scores estimated the probability a child lived in a household with a finished floor conditioning on the following covariates if they were associated with the outcome using a likelihood ratio test (p-value <0.2): month, child age, child sex, birth order (Bangladesh only), mother's age, mother's education, mother's height, number of household members  $\leq 18$  years, total number of individuals in the compound, food insecurity, household assets, and intervention arm.

Outcome	Diagnostic	E-value	E-value CI
Bangladesh			
Hookworm	Kato-Katz	2.43	1.00
T. trichiura	Kato-Katz	2.93	1.25
A. ceylanicum	qPCR	2.58	1.00
A. lumbricoides	qPCR	5.28	1.79
N. americanus	qPCR	3.24	1.31
T. trichiura	qPCR	1.34	1.00
Any STH	qPCR	2.10	1.00
$G. \ du odenalis$	qPCR	1.88	1.28
Kenya			
A. lumbricoides	Kato-Katz	2.27	1.35
Any STH	Kato-Katz	2.40	1.53
A. lumbricoides	qPCR	2.65	1.20
N. americanus	qPCR	2.24	1.00
T. trichiura	qPCR	4.66	1.00
Any STH	qPCR	2.90	1.52
$G. \ du odenalis$	qPCR	1.72	1.23

Appendix Table 9. E-values for adjusted prevalence ratios

E-values quantify the minimum prevalence ratio that an unmeasured confounder would be required to have both household flooring status and each outcome in order for the unmeasured confounder to be completely responsible for a given prevalence ratio. The E-value confidence interval (CI) was calculated for the 95% confidence interval bound closest to the null. E-value CIs were set equal to 1.00 for PR < 1 with upper bounds  $\geq$  1 and for PR > 1 with upper bounds  $\leq$  1 (Vanderweele et al., 2017). Large E-values indicate that an unmeasured confounder would have to have strong associations with both household flooring and an outcome in order to explain away our findings; thus, small E-values are indicate that unmeasured confounding may be a larger concern for a given estimate.

This and abstrate     1     a (a) Indicate the study's design with a commonly used term in the tile or the abstrate     Tile       Interval     (b) Provide in the abstrat an informative and balanced summary of what was done and what was found     Abstract       Interval     (c) Provide in the abstrat an informative and balanced summary of what was done and what was found     Abstract       Background/Fational     2     Explain the scientific background and rationale for the investigation being reported     Introduction       Background/Fational     3     State specific objectives, including any prespecified hypotheses     Introduction       Study design     4     Pescrife the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and ata collection     Methods/Study design, participants       Participants     6     (a) Give the clipbility criteria, and the sources and methods of selection of participants. Describe methods of Subdy design acting in priorito and unexposed     NA       Variables     7     Caerly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnessic in applicable     Methods/Statuscal methods       Variables     8     For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe to another in applicable     Methods/Statuscal methods       Stud size		Item No	Recommendation	Reported in section/sub-section
(b) Provide in the abstract an informative and balanced summary of what was foue and what was found     Abstract       Introduction     2     Explain the scientific background antaionale for the investigation being reported     Introduction       Background/rationale     2     Explain the scientific background antaionale for the investigation being reported     Introduction       Objectives     3     State specific objectives, including any prespecified hypotheses     Introduction       Method     State specific objectives, including any prespecified hypotheses     Methods/Study design       State specific objectives, including any prespecified hypotheses     Methods/Study design, participants       State specific objectives, including any prespecified hypotheses     Methods/Study design, participants       State specific objectives, including enty enty and tate, including periods of recruitment, exposure, follow-up, and data     Methods/Study design, participants       Participants     6     (a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-     Methods/Study design, participants       Variables     7     Clearly define all outcomes, exposure, predictors, potential conformators, and effect motifiers. Give diagnostic     Methods/Study seign       State specific di participant     9     Foreach variable of interest, give sources of b	Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	Title
IntroductionBackground/rationale2Explain the scientific background and rationale for the investigation being reportedIntroductionObjectives3Stat specific objectives, including any prespecified hypothesesIntroductionMethodsPresent code display of the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collectionMethods/Study design, participants collectionParticipants6(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up to Por matched studies, give matching criteria and number of exposed and unexposedMethods/Exposure measurement, outcome measurement, Statistica outcome measurement, Statistica outcome measurement, StatisticaVariables7Clearly define all outcomes, exposures of data and details of methods of assessment (measurement). Describe empatability of assessment methods if there is more than one group comparability of assessment methods if there is more than one group comparability of assessment methods if there is more than one group comparability of assessment methods if there is more than one group comparability of assessment methods if there is more than one group contorem easurement). Describe 			(b) Provide in the abstract an informative and balanced summary of what was done and what was found	Abstract
Background/rationale     2     Explain the scientific background and rationale for the investigation being reported     Introduction       Objectives     3     State specific objectives, including any prespecified hypotheses     Introduction       Methods     -     -     Methods/Study design     Methods/Study design, participants       Setting     4     Present key elements of study design early in the paper     Methods/Study design, participants       Setting     0     Go (ive the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-     Methods/Study design, participants       op     -     -     -     -     -     NA       Variables     7     Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable     Methods/Exposure measurement, statistical methods of assessment (measurement). Describe     Methods/Statiscial methods       Bas ources/     8     For each variable of interest, give sources of bias     Methods/Study size     Methods/Study size       Quantitative     10     Explain how the study size was arrived at     Methods/Study size     Methods/Study size       Variables     10     Explain how the study size was arrived at	Introduction			
Objectives     3     State specific objectives, including any prespecified hypotheses     Introduction       Methods      Methods/Study design     4     Present key elements of study design early in the paper     Methods/Study design, participants       Setting     5     Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and date Study design, participants     Methods/Study design       Participants     6     (a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up     Methods/Participants       Variables     7     Clarely define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic     Methods/Exposure measurement, outcome measurement, Statistical       Data sources/     8*     For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe     Methods/Statistical methods       Bias     9     Describe any efforts to address potential sources of bias     Methods/Statistical methods       Study size     10     Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were     Methods/Statistical methods       variables     6     Observibe and why     Statisticial methods       Statistical meth	Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	Introduction
Methods     Study design     4     Present key elements of study design early in the paper     Methods/Study design       Setting     5     Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection     Methods/Study design, participants       Participants     6     (a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow- up     Methods/Participants       Variables     7     Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable     Methods/Exposure measurement, outcome measurement, statistical       Data sources/     8*     For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe measurement     Methods/Statistical methods       Biads     9     Describe any efforts to address potential sources of bias     Methods/Statistical methods       Study size     10     Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were (b) Describe any methods used to examine subgroups and interactions (c) Explain how quantitative analyse used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (c) Explain how missing data were ad	Objectives	3	State specific objectives, including any prespecified hypotheses	Introduction
Study design     4     Present key elements of study design early in the paper     Methods/Study design,       Setting     5     Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data     Methods/Study design, participants       Participants     6     (a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up, and data     Methods/Participants       Variables     7     Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable     Methods/Exposure measurement, statistical methods       Data sources/     8*     For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe methods if there is more than one group     Methods/Exposure measurement, statistical methods       Bias     9     Describe any efforts to address potential sources of bias     Methods/Statistical methods       Study size     10     Explain how the study size was arrived at     Methods/Statistical methods       Variables     (a) Describe any efforts to address potential sources of bias     Methods/Statistical methods       Study size     10     Explain how the study size was arrived at     Methods/Statistical methods       Variables     (a) Describe any methods u	Methods			
Setting 5 Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, followup, and data collection Methods/Study design, participants   Participants (a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow up Methods/Participants   Variables 7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable Methods/Exposure measurement, outcome measurement, Statistical methods   Data sources/ 8* For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe measurement Methods/Exposure measurement, outcome measurement   Bias 9 Describe any efforts to address potential sources of bias Methods/Statistical methods   Study size 10 Explain how that variables were handled in the analyses. If applicable, describe which groupings were chosen and why Methods/Study size   Statistical methods 1 (a) Describe any methods including these used to control for confounding (b) Describe any mising data were addressed Methods/Statistical methods   (b) Describe any sensitivity analyses Methods/statistical methods Methods/Statistical methods	Study design	4	Present key elements of study design early in the paper	Methods/Study design
Participants     6 (a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow- up     Methods/Participants       Variables     7 (b) For matched studies, give matching criteria and number of exposed and unexposed     NA       Variables     7 (criteria, if applicable     Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable     Methods/Exposure measurement, outcome measurement, settods       Data sources/ measurement     8* (comparability of assessment methods if there is more than one group     Methods/Exposure measurement, outcome measurement       Bias     9     Describe any efforts to address potential sources of bias     Methods/Statistical methods       Study size     10     Explain how the study size was arrived at     Methods/Statistical methods       Quantitative     11     Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were (b) Describe any methods used to examine subgroups and interactions     Methods/Statistical methods       (b) Describe any methods used to examine subgroups and interactions     Methods/Statistical methods       (b) Describe any methods used to examine subgroups and interactions     Methods/Statistical methods       (c) Explain how missing data were addressed     NA       (d) If applicable, explain h	Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Methods/Study design, participants
(b) For matched studies, give matching criteria and number of exposed and unexposed   NA     Variables   7   Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable   Methods/Exposure measurement, Statistical methods     Data sources/   8*   For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe   Methods/Exposure measurement, Statistical methods     Bias   9   Describe any efforts to address potential sources of bias   Methods/Statistical methods     Study size   10   Explain how the study size was arrived at   Methods/Study size     Quantitative   11   Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were   Methods/Study size     Statistical methods   16   Observibe any methods used to examine subgroups and interactions   Methods/Statistical methods     Variables   10   Explain how quantitative variables were addressed   Methods/Statistical methods     (b) Describe any methods used to examine subgroups and interactions   Methods/Statistical methods   Methods/Statistical methods     (c) Explain how missing data were addressed   NA   NA   NA     (d) If applicable, explain how loss to follow-up was addressed   NA   NA	Participants	6	( <i>a</i> ) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	Methods/Participants
Variables   7   Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable   Methods/Exposure measurement, outcome measurement, Statistical methods     Data sources/   8*   For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group   Methods/Exposure measurement, outcome measurement     Bias   9   Describe any efforts to address potential sources of bias   Methods/Statistical methods     Study size   10   Explain how the study size was arrived at   Methods/Study size     Quantitative   11   Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why   Methods/Outcome measurement, Statistical methods     Statistical methods   [d]   Quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why   Methods/Statistical methods     Statistical methods   [d]   Describe any methods used to examine subgroups and interactions   Methods/Statistical methods     (c) Explain how missing data were addressed   NA   NA   NA     (c) Explain how missing data were addressed   NA   NA     (c) Describe any sensitivity analyses   Methods/Statistical methods   NA <			(b) For matched studies, give matching criteria and number of exposed and unexposed	NA
criteria, if applicable   outcome measurement, Statistical methods     Data sources/   8*   For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe   Methods/Exposure measurement, and the assessment (measurement). Describe     Bias   9   Describe any efforts to address potential sources of bias   Methods/Statistical methods     Study size   10   Explain how the study size was arrived at   Methods/Study size     Quantitative   11   Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were   Methods/Study size     Statistical methods   6   Opescribe any methods, including those used to control for confounding   Methods/Statistical methods     Statistical methods   6   Describe any methods used to examine subgroups and interactions   Methods/Statistical methods     (b) Describe any methods used to examine subgroups and interactions   Methods/Statistical methods   NA     (c) Explain how missing data were addressed   NA   NA     (c) Describe any sensitivity analyses   Methods/Statistical methods   NA     (c) Describe any sensitivity analyses   Statistical methods   NA     (c) Describe any sensitivity analyses   Methods/Statistical methods	Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic	Methods/Exposure measurement,
methods     Data sources/   8*   For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe   Methods/Exposure measurement, outcome measurement, outcome measurement     measurement   comparability of assessment methods if there is more than one group   outcome measurement     Bias   9   Describe any efforts to address potential sources of bias   Methods/Statistical methods     Study size   10   Explain how the study size was arrived at   Methods/Study size     Quantitative   11   Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were   Methods/Outcome measurement, othods     variables   chosen and why   Statistical methods, including those used to control for confounding   Methods/Statistical methods     (b) Describe any methods used to examine subgroups and interactions   Methods/Statistical methods   NA     (c) Explain how missing data were addressed   NA   NA     (c) Describe any sensitivity analyses   Methods/Statistical methods   NA     (d) If applicable, explain how loss to follow-up was addressed   NA   NA     (c) Describe any sensitivity analyses   Methods/Statistical methods   NA			criteria, if applicable	outcome measurement, Statistical
Data sources/8*For each variable of interest, give sources of data and details of methods of assessment (measurement). DescribeMethods/Exposure measurement, outcome measurementmeasurementcomparability of assessment methods if there is more than one groupoutcome measurementBias9Describe any efforts to address potential sources of biasMethods/Statistical methodsStudy size10Explain how the study size was arrived atMethods/Study sizeQuantitative11Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings wereMethods/Outcome measurement, Statistical methodsVariables(a) Describe and whyStatistical methodsMethods/Statistical methodsStatistical methods(b) Describe any methods used to examine subgroups and interactionsMethods/Statistical methods(b) Describe any methods used to follow-up was addressedNANA(c) Describe any sensitivity analysesNANA(c) Describe any sensitivity analysesMethods/Statistical methods				methods
measurementcomparability of assessment methods if there is more than one groupoutcome measurementBias9Describe any efforts to address potential sources of biasMethods/Statistical methodsStudy size10Explain how the study size was arrived atMethods/Study sizeQuantitative11Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings wereMethods/Outcome measurement, Statistical methodsvariables12(a) Describe all statistical methods, including those used to control for confoundingMethods/Statistical methodsStatistical methods12(a) Describe any methods used to examine subgroups and interactionsMethods/Statistical methods(b) Describe any methods used to examine subgroups and interactionsMethods/Statistical methodsNA(d) If applicable, explain how loss to follow-up was addressedNA(e) Describe any sensitivity analysesMethods/Statistical methods	Data sources/	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe	Methods/Exposure measurement,
Bias9Describe any efforts to address potential sources of biasMethods/Statistical methodsStudy size10Explain how the study size was arrived atMethods/Study sizeQuantitative11Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings wereMethods/Outcome measurement,variableschosen and whyStatistical methodsStatistical methods12(a) Describe all statistical methods, including those used to control for confoundingMethods/Statistical methods(b) Describe any methods used to examine subgroups and interactionsMethods/Statistical methodsNA(c) Explain how missing data were addressedNA(d) If applicable, explain how loss to follow-up was addressedNA(e) Describe any sensitivity analysesMethods/Statistical methods	measurement		comparability of assessment methods if there is more than one group	outcome measurement
Study size10Explain how the study size was arrived atMethods/Study sizeQuantitative11Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings wereMethods/Outcome measurement, Statistical methodsvariableschosen and whyStatistical methods, including those used to control for confoundingMethods/Statistical methodsStatistical methods12(a) Describe all statistical methods, including those used to control for confoundingMethods/Statistical methods(b) Describe any methods used to examine subgroups and interactionsMethods/Statistical methodsNA(c) Explain how missing data were addressedNA(d) If applicable, explain how loss to follow-up was addressedMethods/Statistical methods(e) Describe any sensitivity analysesMethods/Statistical methods	Bias	9	Describe any efforts to address potential sources of bias	Methods/Statistical methods
Quantitative   11   Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were   Methods/Outcome measurement,     variables   chosen and why   Statistical methods   Statistical methods     Statistical methods   12   (a) Describe all statistical methods, including those used to control for confounding   Methods/Statistical methods     (b) Describe any methods used to examine subgroups and interactions   Methods/Statistical methods     (c) Explain how missing data were addressed   NA     (d) If applicable, explain how loss to follow-up was addressed   NA     (e) Describe any sensitivity analyses   Methods/Statistical methods	Study size	10	Explain how the study size was arrived at	Methods/Study size
variableschosen and whyStatistical methodsStatistical methods12(a) Describe all statistical methods, including those used to control for confoundingMethods/Statistical methods(b) Describe any methods used to examine subgroups and interactionsMethods/Statistical methods(c) Explain how missing data were addressedNA(d) If applicable, explain how loss to follow-up was addressedNA(e) Describe any sensitivity analysesMethods/Statistical methods	Quantitative	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were	Methods/Outcome measurement,
Statistical methods   12   (a) Describe all statistical methods, including those used to control for confounding   Methods/Statistical methods     (b) Describe any methods used to examine subgroups and interactions   Methods/Statistical methods     (c) Explain how missing data were addressed   NA     (d) If applicable, explain how loss to follow-up was addressed   NA     (e) Describe any sensitivity analyses   Methods/Statistical methods	variables		chosen and why	Statistical methods
(b) Describe any methods used to examine subgroups and interactionsMethods/Statistical methods(c) Explain how missing data were addressedNA(d) If applicable, explain how loss to follow-up was addressedNA(e) Describe any sensitivity analysesMethods/Statistical methods	Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	Methods/Statistical methods
(c) Explain how missing data were addressedNA(d) If applicable, explain how loss to follow-up was addressedNA(e) Describe any sensitivity analysesMethods/Statistical methods			(b) Describe any methods used to examine subgroups and interactions	Methods/Statistical methods
(d) If applicable, explain how loss to follow-up was addressed   NA     (e) Describe any sensitivity analyses   Methods/Statistical methods			(c) Explain how missing data were addressed	NA
(e) Describe any sensitivity analyses Methods/Statistical methods			(d) If applicable, explain how loss to follow-up was addressed	NA
			( <u>e</u> ) Describe any sensitivity analyses	Methods/Statistical methods

### STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

Results

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Results; Appendix Figure 1
		(b) Give reasons for non-participation at each stage	Appendix Figure 1
		(c) Consider use of a flow diagram	Appendix Figure 1
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Table 1
		(b) Indicate number of participants with missing data for each variable of interest	NA
		(c) Summarise follow-up time (eg, average and total amount)	Results
Outcome data	15*	Report numbers of outcome events or summary measures over time	Results
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95%	Results; Figure 1; Figure 2
		confidence interval). Make clear which confounders were adjusted for and why they were included	
		(b) Report category boundaries when continuous variables were categorized	Methods/Outcome measurement
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA
Other analyses	17	Report other analyses done-eg analyses of subgroups and interactions, and sensitivity analyses	Results
Discussion			
Key results	18	Summarise key results with reference to study objectives	Discussion
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Discussion
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Discussion
Generalisability	21	Discuss the generalisability (external validity) of the study results	Discussion
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study	Abstract; Role of the Funding
		on which the present article is based	Source

\*Give information separately for exposed and unexposed groups.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at http://www.strobe-statement.org.